Mounjaro and Ozempic Now Named in GLP-1 Vision-Loss Lawsuits Against Both Drugmakers

What Happened

Newly filed product-liability lawsuits accuse both of the GLP-1 market's dominant drugmakers of causing sudden vision loss, naming Eli Lilly's Mounjaro and Novo Nordisk's Ozempic among the products at issue. The complaints allege that patients prescribed the diabetes therapies later developed NAION (non-arteritic anterior ischemic optic neuropathy) — a rare event in which blood supply to the optic nerve fails, typically blacking out sight in one eye without warning.

The filings widen the ocular litigation beyond the weight-management brands named in earlier claims. Patients taking Zepbound and Wegovy were the first claimant groups; the new suits add people who received the same active molecules — tirzepatide and semaglutide — under their diabetes indications.

Both manufacturers reject the allegations. Lilly and Novo point to randomized-trial safety databases that have not reproduced the NAION signal reported in some observational studies, and each maintains that no causal relationship has been established.

Who Is Affected

• Diabetes patients on Mounjaro or Ozempic who experienced sudden monocular vision loss — the newest claimant pool.
• Eli Lilly and Novo Nordisk, now both formal defendants in vision-loss litigation spanning their highest-volume brands.
• Prescribers, who are expected to document informed-consent conversations about sudden vision changes for every incretin prescription.
• Compounded and gray-market GLP-1 sellers, whose unregulated copies of the same molecules inherit the scrutiny the lawsuits generate.

Timeline

• 2017–2022 — Ozempic (semaglutide) and Mounjaro (tirzepatide) launch for type 2 diabetes; cumulative exposure grows into millions of patient-years.
• 2024 — A Danish population-based study reports elevated NAION incidence among semaglutide users, triggering worldwide regulatory review.
• 2025 — Europe's drug-safety committee concludes a small increase in NAION risk cannot be excluded; rare sudden vision loss is added to GLP-1 product information.
• September 2026 — Lawsuits now name both manufacturers and both flagship diabetes brands, alongside the weight-management claims filed earlier.

What This Means for Researchers

The simultaneous claims against two different molecules give experts something the earlier single-brand suits did not: a natural comparison. Tirzepatide is a dual GIP/GLP-1 receptor agonist; semaglutide acts on GLP-1 receptors alone. If legal discovery surfaces comparable NAION event rates in both safety databases, that argues for a class-level vascular mechanism rather than a molecule-specific flaw. Discovery is also expected to expose adverse-event report volumes and internal safety analyses that researchers have not yet been able to review. The core mechanistic question — rapid metabolic change, vascular effects, or confounding from obesity and diabetes themselves — remains unresolved, and litigation will not answer it. Only well-designed studies with independently verified compounds will.

How to Verify Your Peptides

• Start with how peptide testing works to understand purity, identity, and endotoxin checks.
• For tirzepatide material, see the tirzepatide HPLC testing guide; for semaglutide, the semaglutide purity and COA verification guide.
• A trusted third-party testing lab can independently confirm what you actually received.

Safe Alternatives

Litigation coverage of pharmaceutical brands tends to push some buyers toward unregulated copies — the opposite of what safety demands. If you research these compounds, use our compound profiles for tirzepatide and semaglutide, or explore retatrutide, a next-generation incretin still under clinical study. Our vendor directory ranks suppliers by transparency signals such as published batch testing.

Sources

• Industry reports on product-liability filings (September 2026)
• Regulatory announcements from the European Medicines Agency safety committee (2025)